Please login to the form below

Not currently logged in
Email:
Password:

anaesthetics

This page shows the latest anaesthetics news and features for those working in and with pharma, biotech and healthcare.

Stung by critics, J&J says antidepressant Spravato saves money

Stung by critics, J&J says antidepressant Spravato saves money

It is a single isomer form of ketamine, a low-cost anaesthetic, and ICER says the similarity between the two drugs “raises issues for all stakeholders about how to consider

Latest news

More from news
Approximately 1 fully matching, plus 25 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2016 Deal Watch October 2016

    200+. Janssen / J&J (US). Piramal (IN). Asset acquisition. 5 injectable pain / anaesthetic products.

  • Deal Watch September 2016 Deal Watch September 2016

    500. GSK / Aspen. Asset acquisition. Sale of anaesthetic drugs [Ultiva, Nimbex, Tracrium, Mivacron and Anectinein – excludes US/CA rights].

  • Deal Watch June 2016 Deal Watch June 2016

    Meanwhile AstraZeneca has out-licensed ex-US rights to a portfolio of seven anaesthetics to Aspen. ... Paying $520m upfront Aspen gains access to a series of local anaesthetics including Marcaine (bupivacaine) and Xylocaine (lidocaine/ lignocaine), and

  • Pharma deals in June 2015 Pharma deals in June 2015

    Neosaxitoxin, novel anaesthetic for local anaesthesia and post-op pain management. Collaboration, licence.

  • Pharma deals during March 2014 Pharma deals during March 2014

    Baxter's medical products business has annual sales of over $9bn and a portfolio of intravenous solutions and nutritional therapies, drug delivery systems, premixed and other injectable drugs, inhalation anaesthetics and

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....
The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...

Infographics